Atossa Therapeutics, Inc. (ATOS) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females.
McCune-Albright Syndrome is a rare genetic disorder caused by mutations in the GNAS gene, leading to endocrine abnormalities.
The Rare Pediatric Disease designation is given to drug candidates targeting serious or life-threatening conditions that primarily affect individuals from birth to 18 years of age. If approved, the drug may qualify for a Priority Review Voucher, which can be used to obtain priority review for a future application or sold to another company.
Recent Priority Review Voucher sales have ranged from about $100 million to $205 million.
Atossa shares were up more than 1% in pre-market trading after closing at $5.33 on Friday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.